Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $10.6B | $12.4B | $14.3B | $14.8B | $15.0B | $14.6B | $15.1B | $15.6B | $17.3B | $18.7B | $20.1B | $21.7B | $23.0B | $22.8B | $23.7B | $23.4B | $25.4B | $26.0B | $26.3B | $28.2B |
Discover the top 20 best undervalued stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Nov 2024.
As of today, Amgen Inc.'s last 12-month Revenue is $32.4B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Amgen Inc.'s Revenue growth was 20.9%. The average annual Revenue growth rates for Amgen Inc. have been 8.8% over the past three years, 6.7% over the past five years.
Over the last year, Amgen Inc.'s Revenue growth was 20.9%, which is higher than industry growth of 0.1%. It indicates that Amgen Inc.'s Revenue growth is Good.